Facebook icon Twitter icon Forward icon

NICE guidelines published

Tighter targets for blood sugar levels have been included in the new type 1 diabetes guidance released by the National Institute for Health and Care Excellence (NICE).

The guidance covers type 1 diabetes in adults, type 1 and type 2 diabetes in children and young people, and diabetic foot care. To read more, click here.

New type 1 technology guide released

A new family-friendly guide to type 1 diabetes technology has been launched.

Entitled ‘Type 1 Technology:  A guide for young people and families’, it aims to help families when they are talking to healthcare professionals about the technology on offer to them. 

Different types of insulin pumps, flash glucose monitoring and continuous glucose monitoring are among the technology options covered. To read more, click here.

Five million people at high risk of type 2 diabetes

Five million people in England are at high risk of developing type 2 diabetes, according to a new report published today by Public Health England (PHE).

The estimate of how many people over 16 in England have blood sugar levels in a range indicating a high risk of developing type 2 diabetes, otherwise known as non-diabetic hyperglycaemia, was made in a new a report, compiled by PHE’s National Cardiovascular Health Intelligence Network (NCVIN). To read more, click here.

Weight loss treatment ‘breakthrough’ for type 2 diabetes

A study showing how a newly approved obesity treatment can help shed the pounds in people with Type 2 diabetes represents a breakthrough in weight loss management, according to a leading diabetes researcher.

Professor Melanie Davies, Professor of Diabetes Medicine at the Leicester Research Centre, University of Leicester, led the large international study involving nine countries and believes the findings could prove “significant”. To read more, click here.

Oral treatment trial to continue

The next phase of a trial looking at treating type 2 diabetes orally is to go ahead, it has been announced.

Global healthcare company Novo Nordisk has announced it plans to begin Phase III after “encouraging” results in previous trials.

The programme, named PIONEER, will be made up of seven trials with approximately 8,000 people with type 2 diabetes. To read more, click here.